

INFORMATION DISCLOSURE CITATION IN AN APPLICATION July 29, 2001 (Use several sheets if necessary)				ATTORNEY DOCKET NO. 2134.2006-001		APPLICATION NO.	
				APPLICANT Raymond J. Bergeron, Jr.			
				FILING DATE		GROUP	
1624 JC971 U S P T O 09/98 1986							
U.S. PATENT DOCUMENTS							
EXAM- INER INI- TIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA	3,809,754	05/07/74	Bertrand	424	270	
	AB	3,882,110	05/06/75	Clemence, et al.	260	247.1	
	AC	4,367,233	01/04/83	Clark, et al.	424	270	
	AD	4,406,905	09/27/83	Zähner, et al.	424	263	
	AE	4,457,936	07/03/84	Draeger, et al.	424	270	
	AF	5,840,739	11/24/98	Bergeron, Jr.	514	365	
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES NO
	AL	1292 170	11/10/72	United Kingdom	—	—	
	AM	1320534	13/06/73	Great Britain	—	—	
	AN	2245 560	21/03/74	Germany	—	—	
	AO	2 247 243	09/05/75	France	—	—	
	AP	30 02 989	30/07/81	Germany	—	—	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AR	Abstract for Accession Number 80:146142 from Chemical Abstract Database, 1974.					
	AS	Abstract for Accession Number 83:206330 from Chemical Abstract Database, 1975.					
	AT	Bergeron, "Iron: A Controlling Nutrient in Proliferative Processes," Trends in Biochem. Sci., 11:133-136 (1986).					

PTO-1449 REPRODUCED			ATTORNEY DOCKET NO. 2134.2006-001	APPLICATION NO.
INFORMATION DISCLOSURE CITATION IN AN APPLICATION			APPLICANT Raymond J. Bergeron, Jr.	
July 29, 2001 (Use several sheets if necessary)			FILING DATE 10/17/2001	GROUP 1626
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)				
AU	Bergeron, et al., "Synthesis and Biological Evaluation of Hydroxamate-Based Iron Chelators," <i>J. Med. Chem.</i> , 34:3182-3187 (1991).			
AV	Bergeron, et al., "A Comparison of the Iron-Clearing Properties of 1,2-Dimethyl-3-Hydroxypyrid-4-One 1,2-Diethyl-3-Hydroxypyrid-4-One and Deferoxamine," <i>Blood</i> , 79:1882-1890 (1992).			
AW	Bergeron, et al., "The Desferrithiocin Pharmacophore," <i>J. Med. Chem.</i> , 34:1411-1417 (1994).			
AX	Bickel, et al., "Metabolic Properties of Actinomycetes. Ferrioxamine B," <i>Helv. Chim. Acta</i> , 43:2129-2138 (1960).			
AY	Brittenham, "Pyridoxal Isonicotinoyl Hydrazone: An Effective Iron-Chelator After Oral Administration," <i>Semin. Hematol.</i> , 27:112-116 (1990).			
AZ	Finch, et al., "Ferrokinetics in Man," <i>Medicine (Baltimore)</i> , 49:17-53 (1970).			
AR2	Finch, et al., "Perspectives in Iron Metabolism," <i>N. Engl. J. Med.</i> , 306:1520-1528 (1982).			
AS2	Finch, et al., "Iron Metabolism," <i>Clin. Physiol. Biochem.</i> , 4:5-10 (1986).			
AT2	Ganguly, P.K., and Gupta, B.M., "Antiviral Activity of Isoquinolines Carbazoles and Other Miscellaneous Synthetic Chemicals in Mice," <i>Indian J. Med. Res.</i> , 63(10):1418-1425 (1975).			
AU2	Grady, et al., "Rhodotorulic Acid-Investigation of its Potential as an Iron-Chelating Drug," <i>J. Pharmacol. Exp. Ther.</i> , 209:342-348 (1979).			
AV2	Grady, et al., "HBED: A Potential Oral Iron Chelator," <i>Ann. N.Y. Acad. Sci.</i> , 612:361-368 (1990).			
AW2	Guterman, et al., "Feasibility of Enterochelin as an Iron-Chelating Drug: Studies with Human Serum and a Mouse Model System," <i>Gen. Pharmac.</i> , 9:123-127 (1978).			
AX2	Hallberg, "Bioavailability of Dietary Iron in Man," <i>Ann. Rev. Nutri.</i> , 1:123-147 (1981).			
AY2	Hoffbrand, "Transfusion Siderosis and Chelation Therapy," <i>Iron in Biochemistry and Medicine</i> , Volume II, page 449, (London, 1980).			
AZ2	Kishore, V., et al., "Synthesis of α -Poly-[N ^c -(2-aryl-A ³ -thiazoline-4-carbonyl)-L-lysines] with Antiviral Activity," <i>Indian Journal of Chemistry</i> , 15B:255-257 (1977).			
AR3	Kontoghiorghe, et al., "1,2-Dimethyl-3-hydroxypyrid-4-one, an Orally Active Chelator for the Treatment of Iron Overload," <i>Lancet</i> , 1:1294-1295 (1987).			
EXAMINER	DATE CONSIDERED 11/07			

SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION			ATTORNEY DOCKET NO. 2134.2006-001	APPLICATION NO. 09/381,586			
January 09, 2002 (Use several sheets if necessary)			APPLICANT Raymond J. Bergeron, Jr.	JAN 28 2002 U.S. PATENT AND TRADEMARK OFFICE			
			FILING DATE October 17, 2001	GROUP 1626			
U.S. PATENT DOCUMENTS							
EXAM- INER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						RECEIVED
	AD						FEB 04 2002
	AE						TECH CENTER 1600/2900
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB- CLASS	TRANSLATION YES
	AQ	WO94/11367	26-May-94	PCT	—	—	
	AL2	WO97/36885	9-Oct-97	PCT	—	—	
OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)							
	AZ3	Bergeron, R.J., et al. "Evaluation of Desferrithiocin and its Synthetic Analogues as Orally Effective Iron Chelators", Journal of Medicinal Chemistry, (1991), 34(7), 2072-2078					
	AR4	Bergeron, R.J., et al. "Effects of C-4 Stereochemistry and C-4 Hydroxylation on the Iron Clearing Efficiency and Toxicity of Desferrithiocin Analogues", Journal of Medicinal Chemistry, (1999), 42(13), 2432-2440					
	AS4	Jalal, M.A.F., et al. "Structure of Anguibactin, a Unique Plasmid-Related Bacterial Siderophore from the Fish Pathogen Vibrio Anguillarum", Journal of American Chemical Society, (1989), 111(1), 292-296					
EXAMINER				DATE CONSIDERED 10/01			

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION		ATTORNEY DOCKET NO. 2134.2006-001	APPLICATION NO. 09/984,686
JUN 09 2003 JUNE 5, 2003 (Use several sheets if necessary)		APPLICANT Raymond J. Bergeron, Jr.	
		FILING DATE October 17, 2001	CONFIRMATION NO. 7212-162626

RECEIVED
ECA CENTER
JUN 10 2003
162626


U.S. PATENT DOCUMENTS				
EXAM- INER IM- TIAL	REF. NO.	DOCUMENT NUMBER	ISSUE DATE / PUBLICATION DATE	NAME
	AG	2002/0049316 A1	04/25/02	Halbert, et al.
	AH	3,274,207	09/20/66	Kollonitsch, et al.
	AJ	4,457,935	07/03/84	Iwao, et al.
	AJ	4,558,059	12/10/85	Kawasaki, et al.
	AK	4,736,060	04/05/88	Tomuro, et al.
	AA2	4,775,675	10/04/88	Györgydéak, et al.
	AB2	4,902,700	02/20/90	Hayasi, et al.
	AC2	4,914,208	04/03/90	Jakob, et al.
	AD2	5,084,083	01/28/92	Lewis, et al.
	AE2	5,106,992	04/21/92	Magnin, et al.
	AF2	5,169,858	12/08/92	Rubin
	AO2	5,182,402	01/26/93	Lewis, et al.
	AH2	5,192,781	03/09/93	Bru-Magniez, et al.
	AJ2	5,385,922	01/31/95	Bron, et al.
	AJ2	5,393,777	02/28/95	Crosa
	AK2	5,442,073	08/15/95	Eicken, et al.
	AA3	5,614,520	03/25/97	Kondo, et al.
	AB3	6,080,764	06/27/00	Chihiro, et al.
	AC3	6,372,912	04/16/02	Döring, et al.
	AD3	6,437,143	08/20/02	Moinet, et al.
	AE3	5,840,739	11/24/98	Bergeron, Jr.
	AF3	6,083,966	07/04/00	Bergeron, Jr.
	AG3	6,147,070	11/14/00	Facchini
	AH3	6,159,983	12/12/00	Bergeron, Jr.

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION		ATTORNEY DOCKET NO. 2134.2006-001	APPLICATION NO. 09/981,586
JUN 09 2003 JUNE 5, 2003 (Use several sheets if necessary)		APPLICANT Raymond J. Bergeron, Jr.	TECH CENTER 2000 JUN 10 2003 CONFIRMATION NO. 7212 GROUP 26
		FILING DATE October 17, 2001	

RECEIVED

FOREIGN PATENT DOCUMENTS				
	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION YES NO
AM2	EP 0214101 A2	11 MAR 87	Europe	
AN2	EP 0214933 A2	18 MAR 87	Europe	
AO2	EP 0513379 B1	11 SEP 96	Europe	
AP2	WO 99/53039	21 OCT 99	PCT	
AQ2	WO 01/27119 A2	19 APR 01	PCT	
AL3	WO 00/16763	30 MAR 00	PCT	
AM3	1382887	02 MAY 75	United Kingdom	

R6 B/cz



SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION JUN 09 2003 JUNE 5, 2003 <small>(Use several sheets if necessary)</small>		ATTORNEY DOCKET NO. 2134.2006-001	APPLICATION NO. 09/981,585
		APPLICANT Raymond J. Bergeron, Jr.	
		FILING DATE October 17, 2001	CONFIRMATION NO. 7212
			GROUPE 1626

*RECEIVED
TECH CENTER 100-1000
JUN 10 2003*

OTHER DOCUMENTS (<i>Including Author, Title, Date, Pertinent Pages, Etc.</i>)			
	AT4	Fritsch, G., <i>et al.</i> , "Plasmodiumfalciparum: Inhibition in vitro with Lactoferrin, Desferriferrithiocin, and Desferricrocin," <i>Experimental Parasitology</i> 63:1-9 (1987).	
	AU4	Henry, D.W., "Chemotherapeutic Nitroheterocycles. Derivatives of 5-Nitrothiazole-2-carboxaldehyde and 5-Nitrothiazole-2-carboxylic Acid," <i>J. Med. Chem.</i> 12(2):303-306 (1969).	
	AV4	Stahel, E., <i>et al.</i> , "Iron Chelators: In vitro Inhibitory Effect on the Liver Stage of Rodent and Human Malaria," <i>Am. J. Trop. Med.-Hyg.</i> 39(3):236-240 (1988).	
	AW4	Ullmanns Encyclopedia of Industrial Chemistry, 5 th Edition Vol. 14A, "ion exchangers," pp. 446-456, YEAR NOT AVAILABLE	
	AX4	Bergeron, R.J., <i>et al.</i> , "A Comparative Study of the Iron-Clearing Properties of Desferrithiocin Analogues With Desferrioxamine B in a Cebus Monkey Model," <i>Blood</i> , 81(8):2166-2173, (1993).	
	AY4	Bergeron, R.J., <i>et al.</i> , "An Investigation of Desferrithiocin Metabolism," <i>J. Med. Chem.</i> , 37(18):2889-2895, (1994).	
	AZ4	Bergeron, R.J., <i>et al.</i> , "Desazadesmethyldesferrithiocin Analogues as Orally Effective Iron Chelators," <i>J. Med. Chem.</i> , 42(1):95-108, (1999).	
	AR5	Bergeron, R.J., <i>et al.</i> , "Evaluation of the Desferrithiocin Pharmacophore as a Vector for Hydroxamates," <i>J. Med. Chem.</i> , 42(15):2881-2886, (1999).	
	AS5	Bergeron, R.J., <i>et al.</i> , "Evaluation of Desferrithiocin and Its Synthetic Analogues as Orally Effective Iron Chelators," <i>J. Med. Chem.</i> , 34(7):2072-2078, (1991).	
	AT5	Bergeron, R.J., <i>et al.</i> , "Pharmacokinetics of Orally Administered Desferrithiocin Analogs in <i>Cebus Apella</i> Primates," <i>Drug Metabolism and Disposition</i> , 27(12):1496-1498, (1999).	
	AU5	Bergeron, R.J., <i>et al.</i> , "Synthesis and Biological Evaluation of Naphthyldesferrithiocin Iron Chelators," <i>J. Med. Chem.</i> , 39(8):1575-1581, (1996).	
	AV5	Bergeron, R.J., <i>et al.</i> , "The Origin of the Differences in (R)- and (S)-Desmethyldesferrithiocin: Iron-Clearing Properties," <i>Annals of the NY Academy of Sciences</i> , 850:202-216, (1998).	

EXAMINER 	DATE CONSIDERED 11/6/05
--------------	----------------------------

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE CITATION IN AN APPLICATION JUN 09 2003 JUNE 5, 2003 <small>(Use several sheets if necessary)</small>		ATTORNEY DOCKET NO. 2134.2006-001	APPLICATION NO. 09/981,586
		APPLICANT Raymond J. Bergeron, Jr.	
		FILING DATE October 17, 2001	CONFIRMATION NO. 7212
		GROUP 26	JUN 10 2003 RECEIVED USPTO TECH CENTER 2600

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

WS	AWS	Bierer, B.E. and Nathan D.G., "The Effect of Desferrithiocin, an Oral Iron Chelator, on T-Cell Function," <i>Blood</i> , 76(10):2052-2059, (1990).
WS	AX5	Cragg, L., <i>et al.</i> , "The Iron Chelator L1 Potentiates Oxidative DNA Damage in Iron-Loaded Liver Cells," <i>Blood</i> , 92(2):632-638, (1998).
WS	AY5	Dean, R.T. and Nicholson, P., "The Action of Nine Chelators on Iron-Dependent Radical Damage," <i>Free Rad. Res.</i> , 20(2):83-101, (1994).
WS	AZ5	Re, R., <i>et al.</i> , "Antioxidant Activity Applying an Improved ABTS Radical Cation Decolorization Assay," <i>Free Rad. Biol. Med.</i> , 26(9/10):1231-1237, (1999).
WS	AR6	Abstract No. NDN-050-0012-6956-2 obtained from Nerac for EP 0214101 A2; Publication date 11 MAR 87.
WS	AS6	Abstract No. NDN-050-0012-7442-9 obtained from Nerac for EP 0214933 A2; Publication date 18 MAR 87.

EXAMINER <i>Lam L. Stock</i>	DATE CONSIDERED 11/6/05
---------------------------------	----------------------------